Future marketing of ephedrine "street drugs" is "irresponsible," FDA tells six companies.
This article was originally published in The Tan Sheet
CONTINUED MARKETING OF EPHEDRINE "STREET DRUGS" IS "IRRESPONSIBLE," FDA tells six companies in Aug. 19 letters. The letters target firms that manufacture or distribute ephedrine-containing street drug knock-offs that claim to "cause such effects as euphoria, increased sexual sensations, and/or heightened awareness."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC